Author Login

Correspondence to Author: Etycha Kioui, Vaiiki Lyraki, Gegia Lamprii Mardki, Niolna Schika, Aikerini Konantina Daiaou, Chriina Pangiotis Malinou, Niklaos Syrgos, Gorgia Gomtou, Elis Kteas. 

Department of Orthodontics, Lutheran University of Brazil, Canoas, Rio Grande do Sul, Brazil

Abstract:

The introduction of immune checkpoint inhibitors in the therapeutics of non-small celllung cancer (NSCLC) has been a game-changer in the management of patients with lung cancer;however, challenges do exist since a non-negligible subset of patients does not respond to therapy. Various immunotherapeutic anticancer strategies have been increasingly developed in recent years,including monoclonal antibodies, adoptive T-cell therapy, and vaccines. Fueled by their rapiddrug development and successful implementation during the COVID-19 pandemic, messenger RNA (mRNA) vaccines represent an emerging therapeutic approach in other fields of medicine,including oncology. Several clinical trials are currently being conducted to assess the safety and efficacy of mRNA vaccines regarding a variety of solid tumors.Additionally, it has been proposed and is presently being researched to combine mRNA vaccines with other immunotherapeutic strategies.Even while the inquiry into NSCLC is still in its early phases, the preliminary findings raise the necessity of educating clinicians about these potential treatments. In light of this, the goal of this study is to provide an overview of recent developments in mRNA vaccine development for NSCLC treatments, as well as to address practical issues pertaining to their medication creation and various implementation prospects.
Simple Summary: Adoptive T-cells, mRNA vaccines, and monoclonal antibodies are all part of the fast evolving field of cancer immunotherapy. Because of their widespread application during the COVID-19 pandemic, mRNA vaccines are showing promise as a treatment approach for a number of medical specialties, including oncology. The purpose of several clinical trials is to assess the effectiveness and safety of these vaccinations in the management of solid tumors. Numerous investigations are underway to examine the potential of mRNA vaccines in conjunction with other immunotherapeutic medications and techniques. Research on NSCLC has not yet produced outcomes that will change practice. Nonetheless, given the current findings of the ongoing research, it is imperative that clinicians become more knowledgeable about this therapeutic method.Thus, the purpose of this review is to outline the advancements and challenges in the creation of mRNA vaccines for the treatment of non-small cell lung cancer (NSCLC) as well as potential applications in clinical settings.

Keywords: Lung cancer, NSCLC, messenger RNA, mRNA vaccines, and anticancer vaccinations

Citation:

Dr.Etycha Kioui, Developments And Difficulties Of Messenger Rna Vaccines In Nsclc Therapy. Advances in Vaccines 2025.